Press Release Archives
Bellerophon Therapeutics Inc
Bellerophon Therapeutics, Inc. engages in developing products at the intersection of drugs and devices. Its products are using in the treatment of cardiopulmonary and cardiac diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, NJ.

Bellerophon Therapeutics Inc Press Releases

Press Archives

Bellerophon Therapeutics Inc

Press Archives

Bellerophon Presents New Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting

Oct 23rd 2019

Bellerophon to Host Key Opinion Leader Meeting Focused on Pulmonary Hypertension Associated with Interstitial Lung Disease

May 22nd 2019

Bellerophon Presents Additional Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference

May 21st 2019

Results Presented in Late-Breaking Abstract as an Oral Presentation

Bellerophon to Present Additional Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference

May 13th 2019

May 13, 2019 Results to be Presented in Late-Breaking Abstract as an Oral Presentation Company will Also Present a Corporate Overview and Update on its PH

Bellerophon Provides Business Update and Reports First Quarter 2019 Financial Results

May 9th 2019

May 9, 2019 WARREN, N.J., May 09, 2019 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clini

Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Apr 8th 2019

April 8, 2019 FDA Agrees to Primary Endpoint of Change in Moderate to Vigorous Physical Activity from Baseline to Week 16, Measured by Actigraphy FDA Also

Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2018 Financial Results

Mar 14th 2019

March 14, 2019 WARREN, N.J., March 14, 2019 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a

Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients  

Jan 28th 2019

January 28, 2019 Actigraphy is Being Utilized to Evaluate Multiple Clinically Meaningful Activity Parameters in the Ongoing INOpulse® Phase 2b Clinica

Bellerophon Announces Closing of $7 Million Public Offering of Common Stock

Jan 25th 2019

January 25, 2019 WARREN, N.J., Jan. 25, 2019 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a

Bellerophon Announces Pricing of $7 Million Public Offering of Common Stock

Jan 23rd 2019

January 23, 2019 WARREN, N.J., Jan. 23, 2019 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a

Bellerophon Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jan 22nd 2019

January 22, 2019 WARREN, N.J., Jan. 22, 2019 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a

Bellerophon Announces Top-line Results from Cohort 1 of the INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Jan 7th 2019

Statistically Significant Improvements in Multiple Clinically Meaningful Activity Parameters Demonstrated